Skip to main content

Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.’s Biotech Conference on November 30, 2022.

Robert W. Mays, M.D., Ph.D., Executive Vice President and Head of Regenerative Medicine & Neuroscience, will speak in a keynote panel at the Challenges and Opportunities for Mesenchymal Stem Cells digital conference on November 17. Dr. Mays will be speaking in his area of expertise, joining other industry experts to discuss clinical trial design, overcoming challenges in the clinical setting, and more.

The following are specific details regarding Athersys’ participation at the Challenges and Opportunities for Mesenchymal Stem Cells conference:


Challenges and Opportunities for Mesenchymal Stem Cells


What are the Current Barriers for Success?


Nitsan Halevy, CMO, Pluristem


Robert Mays, Executive VP, Athersys

Pawan Gupta, VP, Medical Affairs, Stempeutics


Thursday, November 17, 2022


8:05 AM Eastern Time



A live video webcast of all content from the digital conference will be available for registered participants during the conference and for 10 business days post-event. Please visit for detailed conference information and registration.

Additionally, members of Athersys management will be attending A.G.P.’s Biotech Conference on November 30 and will be participating in one-on-one meetings with institutional investors registered with the conference. Investors interested in arranging a meeting with members of the Company’s management during the conference should contact

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at and on our social media accounts. Follow Athersys on Twitter at Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

About MultiStem®

MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.



Ellen Gurley

Manager of Corporate Communications and Investor Relations

LHA Investor Relations

Tirth T. Patel


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.